Statins are the first-line treatment for high cholesterol, with high-intensity options like atorvastatin and rosuvastatin cutting LDL by 50% or more. When statins alone aren't enough, ezetimibe can add a further 15–20% reduction, and PCSK9 inhibitors offer dramatic lowering for high-risk patients or those with familial hypercholesterolemia. Whether medication is needed at all depends on your overall cardiovascular risk — not just your cholesterol number.
Cholesterol-Lowering Medications: Statins and Beyond
Cholesterol is a waxy, fat-like substance found in every cell of the body — essential for producing hormones, vitamin D, and bile acids. The problem is not cholesterol itself, but its behavior when certain types accumulate in the bloodstream. Low-density lipoprotein (LDL), often called "bad" cholesterol, carries cholesterol into arterial walls where it can oxidize and trigger inflammation, forming the plaques that underlie atherosclerosis. High-density lipoprotein (HDL), the "good" cholesterol, helps shuttle cholesterol back to the liver for excretion. Triglycerides are a separate blood fat; very-low-density lipoprotein (VLDL) is the primary triglyceride-carrying particle and a contributor to atherosclerosis in its own right.
Elevated LDL is causally linked to myocardial infarction, ischemic stroke, and peripheral arterial disease. The longer LDL remains elevated and the more arterial exposure accumulates over a lifetime, the greater the plaque burden. This is why treatment decisions are not made on cholesterol numbers alone, but on overall cardiovascular risk. Clinicians use tools like the Pooled Cohort Equations to estimate a patient's 10-year risk of a major atherosclerotic cardiovascular event (ASCVD) — a heart attack or stroke. The result helps determine whether medication is warranted, and how aggressively to treat.
Primary prevention refers to reducing the risk of a first cardiovascular event; secondary prevention means preventing a second event in a patient who has already had a heart attack, stroke, or was diagnosed with peripheral arterial disease. Secondary prevention patients generally need intensive lipid-lowering regardless of their baseline LDL number, since the benefit-to-risk ratio of treatment is extremely favorable.
Statins — The Foundation of Lipid Therapy
Statins are the most prescribed cardiovascular medications in the world, and for good reason: they have the most robust evidence for reducing heart attacks and strokes of any lipid-lowering drug class. Their mechanism centers on inhibiting HMG-CoA reductase, the enzyme that controls the rate-limiting step of cholesterol synthesis in the liver. When the liver produces less cholesterol internally, it compensates by upregulating LDL receptors on its surface — pulling more LDL out of the bloodstream to meet its needs. The net result is a sustained, meaningful reduction in circulating LDL.
Statins are classified by intensity. High-intensity statins — atorvastatin 40–80 mg (Lipitor) and rosuvastatin 20–40 mg (Crestor) — reduce LDL by 50% or more. These are preferred for patients with established cardiovascular disease or very high risk. Moderate-intensity regimens, such as atorvastatin 10–20 mg, rosuvastatin 5–10 mg, simvastatin 20–40 mg, pravastatin 40–80 mg, or lovastatin 40 mg, achieve 30–50% LDL reduction. Low-intensity statins are rarely used in current practice.
Simvastatin (Zocor) deserves a special note: at doses of 80 mg, it carries a significantly higher risk of myopathy than other statins at equivalent efficacy, leading the FDA to restrict that dose. Many prescribers now avoid simvastatin 80 mg entirely, opting instead for higher-potency agents like rosuvastatin or atorvastatin.
Four patient groups benefit most clearly from statin therapy per ACC/AHA guidelines: those with clinical ASCVD (prior heart attack, stroke, or PAD); LDL ≥190 mg/dL; adults aged 40–75 with diabetes; and adults aged 40–75 with a 10-year ASCVD risk ≥7.5% and LDL ≥70 mg/dL.
Side effects are worth understanding in context. Myalgia — muscle aching or weakness — is the most commonly reported complaint, affecting up to 10% of patients in observational studies, though randomized controlled trials (which control for the nocebo effect) show a much smaller attributable rate. Most muscle symptoms are mild and reversible with dose reduction or a switch to a different statin. True myopathy with significant creatine kinase (CK) elevation is rare; rhabdomyolysis (severe muscle breakdown leading to kidney injury) is exceedingly rare with monotherapy. If a patient reports severe muscle pain, checking a CK level is appropriate. A modest increase in fasting glucose and a small elevation in liver transaminases can also occur; routine repeat liver function testing is no longer recommended by ACC/AHA guidelines unless symptoms arise.
Ezetimibe — The Add-On That Works
Ezetimibe (Zetia) takes a completely different approach to lowering LDL: instead of reducing how much cholesterol the liver makes, it reduces how much cholesterol the intestine absorbs from food and bile. It accomplishes this by blocking NPC1L1, a transporter protein located in the brush border of intestinal cells. Less cholesterol enters the body from the gut, which in turn signals the liver to further upregulate its LDL receptors.
Used alone, ezetimibe lowers LDL by about 15–20% — less than a high-intensity statin, but meaningful. Its real power is as an add-on to statin therapy: when combined with a statin that has already cleared the obvious pathways, blocking intestinal absorption adds an additional 15–20% reduction on top. Ezetimibe is now available as a generic, making it inexpensive and widely accessible.
The IMPROVE-IT trial established that adding ezetimibe to simvastatin in patients who had recently experienced an acute coronary syndrome (ACS) produced a modest but statistically significant reduction in cardiovascular events compared to simvastatin alone — confirming that further LDL lowering beyond statin therapy provides incremental benefit. For patients who are truly statin-intolerant, ezetimibe monotherapy offers a reasonable alternative with a very clean side-effect profile.
PCSK9 Inhibitors — Powerful but Expensive
PCSK9 (proprotein convertase subtilisin/kexin type 9) is a protein that the liver normally uses to degrade its own LDL receptors — essentially a feedback mechanism to prevent excessive cholesterol clearance. Blocking PCSK9 means LDL receptors survive longer on the liver cell surface and clear far more LDL from the blood. The result is dramatic: evolocumab (Repatha) and alirocumab (Praluent), both injectable monoclonal antibodies administered every two to four weeks, can reduce LDL by 50–60% on top of a maximally tolerated statin and ezetimibe combination.
These medications are indicated for patients with familial hypercholesterolemia — a genetic disorder causing severely elevated LDL from birth — and for patients with established cardiovascular disease who cannot reach their LDL goal despite maximum-dose statin plus ezetimibe. Large outcomes trials (FOURIER for evolocumab, ODYSSEY OUTCOMES for alirocumab) confirmed significant reductions in cardiovascular events. The barrier is cost: list prices run into the thousands of dollars per month, though patient assistance programs and biosimilar approvals are gradually improving access.
Inclisiran (Leqvio) represents a newer approach: a small interfering RNA (siRNA) that silences the PCSK9 gene in hepatocytes, reducing how much PCSK9 protein is produced in the first place. Given as an injection only twice per year (after two initial doses), it achieves similar LDL reductions with exceptional dosing convenience.
Fibrates — For High Triglycerides
Fibrates — primarily fenofibrate (Tricor, Fenoglide) and gemfibrozil (Lopid) — act primarily on triglyceride metabolism rather than LDL. They activate PPAR-alpha, a nuclear receptor that upregulates lipoprotein lipase activity and reduces VLDL production, resulting in triglyceride reductions of 30–50% and modest HDL increases of 10–15%. Their effect on LDL is variable and often small.
The principal indication for fibrates today is severe hypertriglyceridemia — triglyceride levels above 500 mg/dL — where the risk of acute pancreatitis becomes a real concern. Whether fibrates reduce cardiovascular events is less settled than with statins; major outcome trials have shown mixed results, and current guidelines do not endorse fibrates as primary cardiovascular prevention agents for most patients.
Important drug interaction: gemfibrozil significantly inhibits statin metabolism, raising statin blood levels and dramatically increasing the risk of myopathy and rhabdomyolysis. If a fibrate must be combined with a statin, fenofibrate is strongly preferred because it does not share this interaction to the same degree.
Who Needs Medication vs. Lifestyle Only
Lifestyle modification can meaningfully reduce LDL — typically by 10–20% — through a combination of dietary changes, exercise, and weight loss. Reducing saturated fat and eliminating trans fats lowers LDL by reducing hepatic cholesterol synthesis and promoting LDL receptor activity. Adding soluble fiber (oats, legumes, psyllium) and plant sterols or stanols (found in fortified foods or supplements) provides additional modest reductions. Regular aerobic exercise raises HDL and lowers triglycerides, though its direct effect on LDL is more modest.
For a patient with borderline-elevated LDL and a low 10-year ASCVD risk — say, a healthy 45-year-old with no other risk factors and a risk score under 5% — lifestyle changes alone may be entirely appropriate. Medication is clearly warranted when any of the following apply: established ASCVD (the evidence for intensive therapy here is overwhelming), familial hypercholesterolemia with LDL ≥190 mg/dL, diabetes in the relevant age group, or a calculated 10-year risk ≥7.5% in conjunction with an LDL that warrants treatment.
The decision is ideally shared between clinician and patient. Risk calculators produce estimates, not certainties. Factors like a high coronary artery calcium (CAC) score on imaging can reclassify risk upward for borderline patients; patient preference, cost concerns, and comorbidities all shape the final choice.
Monitoring and Statin Tolerance
When starting a statin, a fasting lipid panel should be repeated 4–12 weeks after initiation to assess response and confirm the patient is at goal. Annual lipid monitoring is appropriate thereafter for stable patients. Baseline liver function tests were once routine, but current ACC/AHA guidelines do not require repeated LFTs unless symptoms of liver disease emerge. CK levels are checked only if the patient reports significant muscle symptoms.
Managing statin-associated muscle symptoms requires some detective work. Hypothyroidism, vitamin D deficiency, and vigorous exercise can all cause muscle pain independent of the statin and should be excluded. Strategies for true statin-associated myalgia include reducing the dose, switching to a different statin (pravastatin and rosuvastatin are often better tolerated by patients who struggled with atorvastatin or simvastatin), or using alternate-day dosing with longer-half-life statins like rosuvastatin. Coenzyme Q10 supplementation is frequently tried by patients and is harmless, though randomized evidence for its benefit in statin myalgia is inconsistent. For the small subset of patients with true statin intolerance, the combination of ezetimibe plus a PCSK9 inhibitor can achieve substantial LDL reduction without any statin.
Frequently Asked Questions
What medications are used to treat high cholesterol?
Statins (atorvastatin, rosuvastatin, simvastatin) are the first-line treatment for most patients with high LDL cholesterol and are the most evidence-supported drugs for reducing cardiovascular events. Beyond statins, ezetimibe reduces cholesterol absorption in the gut and is often added when statins alone are insufficient. PCSK9 inhibitors (evolocumab, alirocumab) are injectable medications that dramatically lower LDL and are used for very high-risk patients or those who cannot tolerate statins. Fibrates primarily target triglycerides. Niacin is less commonly used today due to modest cardiovascular benefits in modern trials.
What are the side effects of statins?
The most commonly reported statin side effect is muscle aching or weakness — called myalgia — which affects some patients and often resolves with a switch to a different statin or a lower dose. Serious muscle damage (rhabdomyolysis) is rare but documented. Statins also carry a small increased risk of new-onset type 2 diabetes and mild liver enzyme elevations. For the vast majority of patients at elevated cardiovascular risk, the benefit of statins in reducing heart attacks and strokes substantially outweighs these risks.
Do I need to take cholesterol medication for life?
For most patients taking statins for established cardiovascular disease (secondary prevention), long-term use is standard practice — the cardiovascular benefits are ongoing. For patients taking statins primarily to prevent a first event (primary prevention), the decision is more nuanced and depends on overall cardiovascular risk, individual response to lifestyle changes, and patient preference. Most people cannot achieve clinically meaningful LDL reductions through diet alone when their elevated cholesterol is significantly genetic in origin.
Is it safe to take statins if you also drink alcohol?
Moderate alcohol use is generally not contraindicated with statins, but both alcohol and statins are metabolized by the liver. Heavy or chronic alcohol consumption increases the risk of liver-related side effects when combined with statins. People who drink heavily should inform their prescriber before starting statin therapy. Monitoring liver enzymes is appropriate in patients with risk factors for liver disease who are started on statins.
Not sure which cholesterol pill you're looking at?
Identify Your Medication on PillID